A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : hVISA

Search Conditions:
Search Keyword : hVISA
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: hVISA
Appearance Frequency: 216 time(s)
Long forms: 16

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
heterogeneous vancomycin-intermediate S. aureus
(76 times)
Anti-Bacterial Agents
(29 times)
MRSA (47 times)
VISA (21 times)
MICs (10 times)
2001 Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin.
heterogeneous vancomycin-intermediate Staphylococcus aureus
(75 times)
Anti-Bacterial Agents
(28 times)
MRSA (33 times)
VSSA (13 times)
VISA (12 times)
2001 The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model.
heterogeneous VISA
(35 times)
Drug Therapy
(20 times)
VISA (34 times)
MRSA (19 times)
VSSA (11 times)
2004 [Screening for Staphylococcus aureus with a reduced susceptibility to vancomycin in: a Belgian hospital].
heteroresistant VISA
(10 times)
Anti-Bacterial Agents
(7 times)
VISA (10 times)
MRSA (5 times)
VRSA (3 times)
2006 Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin.
heterogeneous intermediate-level resistance to vancomycin
(4 times)
Microbiology
(3 times)
GRD (2 times)
MRSA (2 times)
PAP-AUC (2 times)
2007 Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center.
hetero-VISA
(3 times)
Microbiology
(2 times)
VISA (3 times)
MRSA (2 times)
PAP (1 time)
2008 Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia.
hetero-resistant to vancomycin
(2 times)
Pharmacology
(1 time)
MRSA (2 times)
VAN (1 time)
2010 Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus.
heterogeneous resistance to vancomycin
(2 times)
Microbiology
(1 time)
MRSA (2 times)
CCs (1 time)
GISA (1 time)
2012 Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumonia.
heterogeneous, intermediate-vancomycin-resistant Staphylococcus aureus
(2 times)
Public Health
(1 time)
BHA (1 time)
MHA (1 time)
PAP (1 time)
2006 Detection of heterogeneous, intermediate-vancomycin-resistant Staphylococcus aureus (hVISA) using low-concentration vancomycin disks.
10  hetero-resistance to VAN
(1 time)
Communicable Diseases
(1 time)
MRSA (1 time)
VAN (1 time)
2015 [Isolation of Staphylococcus aureus hetero-resistant to vancomycin (hVISA) in the Regional Hospital of Concepcion, Chile].
11  hetero-vancomycin intermediate-susceptible S. aureus
(1 time)
Drug Therapy
(1 time)
VISA (1 time)
VRSA (1 time)
2004 Glycopeptide resistance in Staphylococcus aureus: is it a real threat?
12  heterogeneously expressed intermediate level glycopeptide resistance
(1 time)
Allergy and Immunology
(1 time)
--- 2004 Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus.
13  heterointermediately resistant to vancomycin
(1 time)
Anti-Bacterial Agents
(1 time)
MRSA (1 time)
2004 Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin.
14  heteroresistant vancomycin-intermediate subpopulations
(1 time)
Communicable Diseases
(1 time)
AOR (1 time)
CI (1 time)
MIC (1 time)
2018 Role of Vancomycin Minimum Inhibitory Concentrations by Modified Population Analysis Profile Method and Clinical Outcomes in High Inoculum Methicillin-Resistant Staphylococcus aureus Infections.
15  vancomycin-heteroresistant
(1 time)
Anti-Bacterial Agents
(1 time)
fAUC (1 time)
MRSA (1 time)
2010 Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
16  vancomycin-heteroresistant S. aureus
(1 time)
Communicable Diseases
(1 time)
MRSA (1 time)
VISA (1 time)
2011 Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naive patient--a review of the literature.